Morgan Stanley Travere Therapeutics, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,650,603 shares of TVTX stock, worth $34.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,650,603

Previous 1,349,408 22.32%

Holding current value

$34.1 Million

Previous $18.9 Million 52.31%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$13.65 - $19.85 $4.11 Million - $5.98 Million	301,195 Added 22.32%	1,650,603 $28.8 Million
Q3 2024 Nov 14, 2024	SELL	$7.89 - $15.21 $16.9 Million - $32.6 Million	-2,140,254 Reduced 61.33%	1,349,408 $18.9 Million
Q2 2024 Oct 17, 2024	SELL	$5.26 - $8.28 $199,659 - $314,292	-37,958 Reduced 1.08%	3,489,662 $28.7 Million
Q2 2024 Aug 14, 2024	SELL	$5.26 - $8.28 $199,659 - $314,292	-37,958 Reduced 1.08%	3,489,662 $28.7 Million
Q1 2024 Oct 17, 2024	BUY	$7.18 - $9.82 $272,538 - $372,747	37,958 Added 1.09%	3,527,620 $27.2 Million
Q1 2024 Aug 16, 2024	SELL	$7.18 - $9.82 $4.37 Million - $5.98 Million	-608,670 Reduced 14.72%	3,527,620 $27.2 Million
Q1 2024 May 15, 2024	SELL	$7.18 - $9.82 $4.37 Million - $5.98 Million	-608,670 Reduced 14.72%	3,527,620 $27.2 Million
Q4 2023 Aug 16, 2024	BUY	$5.44 - $9.5 $3.52 Million - $6.14 Million	646,628 Added 18.53%	4,136,290 $37.2 Million
Q4 2023 Feb 13, 2024	BUY	$5.44 - $9.5 $10.3 Million - $18 Million	1,895,953 Added 84.63%	4,136,290 $37.2 Million
Q3 2023 Nov 15, 2023	BUY	$7.64 - $17.25 $11 Million - $24.9 Million	1,441,558 Added 180.47%	2,240,337 $20 Million
Q2 2023 Aug 14, 2023	SELL	$15.3 - $22.61 $1.45 Million - $2.15 Million	-95,091 Reduced 10.64%	798,779 $12.3 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $3.59 Million - $4.62 Million	201,666 Added 29.13%	893,870 $20.1 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $5.89 Million - $8.34 Million	319,136 Added 85.54%	692,204 $14.6 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $4.87 Million - $6.09 Million	-212,705 Reduced 36.31%	373,068 $9.19 Million
Q2 2022 Oct 27, 2022	BUY	$20.94 - $30.01 $2.09 Million - $3 Million	99,831 Added 20.54%	585,773 $14.2 Million
Q2 2022 Aug 15, 2022	BUY	$20.94 - $30.01 $2.09 Million - $3 Million	99,831 Added 20.54%	585,773 $14.2 Million
Q1 2022 Oct 27, 2022	SELL	$23.61 - $30.6 $2.36 Million - $3.05 Million	-99,831 Reduced 17.04%	485,942 $12.5 Million
Q1 2022 May 13, 2022	BUY	$23.61 - $30.6 $4.11 Million - $5.33 Million	174,135 Added 55.85%	485,942 $12.5 Million
Q4 2021 Feb 14, 2022	SELL	$24.34 - $31.17 $1.68 Million - $2.15 Million	-69,128 Reduced 18.15%	311,807 $9.68 Million
Q3 2021 Nov 15, 2021	BUY	$12.98 - $25.03 $4.94 Million - $9.53 Million	380,935 New	380,935 $9.24 Million

Others Institutions Holding TVTX

# of Institutions

213

Shares Held

94.1M

Call Options Held

1.2M

Put Options Held

778K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.33B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account